Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9343(57)90303-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Saving Legs & Lives: the efficacy of a community-based cardiovascular rehabilitation programme versus usual care on exercise capacity and quality of life in patients who have undergone lower limb revascularisation for peripheral arterial disease-protocol for a single-centre randomised-controlled trial.
BMJ Open
December 2024
School of Health, University of the Sunshine Coast, Sippy Downs, Queensland, Australia.
Article Synopsis
- Peripheral artery disease (PAD) causes narrowed arteries in the legs, leading to leg pain during walking, which hampers daily activities; supervised exercise can help improve walking ability.
- This study will compare a cardiovascular rehabilitation (CR) program involving supervised exercise and education with usual care in 66 patients who have recently undergone lower limb revascularisation for PAD.
- The effectiveness of the CR program will be evaluated based on improvements in walking capacity and quality of life over a 6-week period.
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.
J Clin Lipidol
November 2024
Cardiovascular Medicine Division, Brigham and Women's Hospital, Boston, MA, USA (Dr Libby).
Cardiovascular (CV) disease is the most common cause of death in Europe. Despite proven benefits, use of lipid-lowering therapy remains suboptimal. Treatment goals are often not achieved, even in patients at high risk with atherosclerotic CV disease (ASCVD).
View Article and Find Full Text PDFPlasma proteomic comparisons change as coverage expands for SomaLogic and Olink.
medRxiv
July 2024
Departments of Population Health and Medicine, New York University Grossman School of Medicine, New York, New York, United States.
The number of assays on highly-multiplexed proteomic platforms has grown tenfold over the past 15 years from less than 1,000 to >11,000. The leading aptamer-based and antibody-based platforms have different strengths. For example, Eldjarn et al demonstrated that the aptamer-based SomaScan 5k (4,907 assays, assessed in the Icelandic 36K) and the antibody-based Olink Explore 3072 (2,931 assays, assessed in the UK BioBank) had a similar number of -pQTLs among all targets (2,120 vs.
View Article and Find Full Text PDFClinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3.
J Am Coll Cardiol
April 2023
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) levels. Previous clinical trials studying TG-lowering therapies have either failed to reduce major adverse cardiovascular events or shown no linkage of TG reduction with event reduction, particularly when these agents were tested on a background of statin therapy. Limitations in trial design may explain this lack of efficacy.
View Article and Find Full Text PDFClinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
J Am Coll Cardiol
April 2023
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Lipoprotein(a) [Lp(a)] is a source of residual risk in patients with atherosclerotic cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies targeting proprotein convertase subtilisin kexin 9 have shown that reductions in Lp(a) concentrations may be a predictor of event reduction with this class of cholesterol-lowering therapy. With the advent of selective therapies targeting Lp(a) such as antisense oligonucleotides, small-interfering RNA-based therapies, and gene editing, lowering of Lp(a) may lead to reduction in ASCVD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!